Fourteen people no longer have stage 2 or 3 rectal cancer because of an experimental use of immunotherapy. Enrolling in a clinical trial has, for the past 25 months and counting, spared them from surgery, chemotherapy, and radiation, which are the standard treatments for colorectal cancer. [1] Fourteen people may not sound like many, but it...
Read More
Home »
2022 ASCO Annual Meeting
2022 ASCO Annual Meeting Posts on Medivizor
To receive all the
cutting-edge updates personally relevant to you
(free and private)
Categories
- Benign prostatic hyperplasia
- Blog
- Breast cancer
- Cancer
- Colorectal cancer
- Coronary artery disease
- Coronavirus / COVID-19
- Diabetes mellitus
- Erectile dysfunction
- Hodgkin's lymphoma
- Hypertension
- Infertility
- Kidney stones
- Leukemia
- Lung cancer
- Lymphoma
- Melanoma
- Men's Health
- Mental Health
- Multiple Myeloma
- Nocturia
- Non-Hodgkin lymphoma
- Overactive bladder
- Parkinson's Disease
- Prostate cancer
- Rare disease
- Rheumatoid Arthritis
- Stroke
- Urinary incontinence
- Urinary tract infection
Recent Posts
- Movember: More than facial hair–men’s health!
- Unlocking A Mystery: Mast Cells, Hypermobile Ehlers-Danlos Syndrome, and Genes
- Periodontal Disease: Keep your teeth clean for better health
- Evaluating the pulsed solid-state Thulium: YAG laser in men with benign prostatic hyperplasia in a real-world setting
- Comparing the safety and effectiveness of hormonal therapy alone versus chemo-hormonal therapy before prostate surgery in men with locally advanced prostate cancer